ISPOR 12th Annual European Congress 2009
Location
Paris, France
Dates
October 25 - October 27, 2009
Le Palais des Congrès de Paris
Paris, France
During the ISPOR 12th Annual European Congress, Quintiles Market Access and Late Phase experts will lead 3 podium presentations/workshops and displayed 10 posters on a variety of topics. Presentations and posters are listed below:
Podium Presentations
The Role of Patient Registries in Evidence Development: Similarities and Differences Between Europe and North AmericaEric Gemmen -- DSMA
Cost Studies: Estimate Average Costs in the Presence of Right-SensoringS. Guan, P. Peeters, P. Pedotti, AK Van Engen -- Consulting
Cost Studies: Indirect Social Cost of Multiple Sclerosis - Results from a Real-World Observational Study
M. Bharmal - DSMA with S. Kirzinger; J. Halper; D. Jeffery; R. Preblick, YJ Bi; H. JO
Posters
The Relationship Between Drug Utilization and Out of Pocket Expenses for Oral Anti-neoplastics Compared to a Market Basket of Commonly Used Drugs
Sepulveda B, Doyle JJ, White C
Factors Driving Patient Selection of Primary Medications for Multiple Sclerosis
Jeffery D1, Kirzinger S2, Halper J3, Preblick R4, Bi YJ4, Suarez G5, Jo H6, Bharmal M6
Association of Health-Related Quality of Life and Relapse in the Previous Year among Multiple Sclerosis Patients: Baseline Data from Robust
Halper J, Jeffery D, Kirzinger S, Preblick R, Bi YJ, and Gemmen E.
Health Relate Quality of Life, EDSS and Times 25-foot Walk in a Multiple Sclerosis Population of a Real-World Observational Outcomes Study: Baseline Data from RobustJeffery D, Kirzinger S, Halper J, Preblick R, Bi YJ, and Gemmen E.
Evaluating Adverse Event Risk with Propoxyphene: Are there Differences between Elderly Versus Younger Patients?
Bharmal M1, Garvert W2, Jo H2, Gemmen EK1, Hall JR3
Impute Incomplete Patient-level Medical Costs
Guan S1, Peeters P2, Pedotti P1, Van Engen AK1
1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles Consulting, Levallois-Perret, France
Application of HTA to Anti-Diabetic Drug Formulary Decisions
Andreykiv M, Wiebinga C, Quintiles Consulting, Hoofddorp, The Netherlands
A Cost-Effectiveness Analysis of Micafungin versus Caspofungin for Treatment of Systemic Candida Infections in Italy
Sidhu MK1, Van Engen AK2, Switjnk AB2, Concia E3
Medical Resource Utilization and Workdays lost in Patients with Fibromyalgia
Kleintjens J1, Peeters P2, Van Engen AK1, Taylor-Stokes G3, Le Lay K4, Taieb C4
Patient-Reported Outcomes in a Vulnerable Population: A Pilot Study Conducted with a Novel Patient Community
Cascade EF1, Stephenson H2
For more information on our market access solutions: click here.
To learn more regarding our late phase research solutions click here.